Retension Pharmaceuticals Appoints LeAnne Bloedon as EVP of Clinical Development
Position
Executive Vice President
Company
Retension Pharmaceuticals
McleanBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
Retension Pharmaceuticals, Inc. announces the appointment of LeAnne Bloedon as Executive Vice President of Clinical Development and Operations. Additionally, Kevin Schutz will join as Vice President of Regulatory Affairs.
Quick answer
Retension Pharmaceuticals Appoints LeAnne Bloedon as EVP of Clinical Development (September 10, 2026). Retension Pharmaceuticals is based in Mclean, Virginia, United States.
- Who is the new Executive Vice President at Retension Pharmaceuticals?
- Retension Pharmaceuticals named LeAnne Bloedon Executive Vice President, announced September 10, 2026.
- What did Retension Pharmaceuticals announce on September 10, 2026?
- Retension Pharmaceuticals, Inc. announces the appointment of LeAnne Bloedon as Executive Vice President of Clinical Development and Operations. Additionally, Kevin Schutz will join as Vice President of Regulatory Affairs.
- What does Retension Pharmaceuticals do?
- Retension Pharmaceuticals is developing RTN-001, a differentiated, tissue-targeted PDE5 inhibitor that has been optimized for the treatment of uncontrolled hypertension.
- Where is Retension Pharmaceuticals based?
- Retension Pharmaceuticals is based in Mclean, Virginia, United States.
- Which similar companies made leadership changes around the same time?
- Parabilis Medicines (August 25, 2026), Aquestive Therapeutics, Inc. (September 29, 2026), Os Therapies (October 1, 2026) and Abivax (September 7, 2026) also announced leadership changes within 45 days of Retension Pharmaceuticals.
Source: Fundz verified event record.
Other recent leadership changes in Healthcare and Therapeutics
Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.
- Parabilis Medicines Appoints Craig Tendler as Director (August 25, 2026)
- Richard J. Daly Appointed as Director of Aquestive Therapeutics (September 29, 2026)
- OS Therapies Appoints Mr. Clem as Chief Commercial Officer and Mr. Knuettel as Chief Financial Officer (October 1, 2026)
- Abivax Appoints James Berger as Global Head of Marketing (September 7, 2026)
- Arletta Pharma Solutions Appoints Jeannette Jager-van Dijk as Chief Executive Officer (September 1, 2026)
- Adial Pharmaceuticals Appoints Matthew Davidson as President and CEO (August 29, 2026)
Who to call at Retension Pharmaceuticals, and when
A new leader at Retension Pharmaceuticals brings new priorities and often new vendors. The first weeks are when they listen.
- An alert the day Retension Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Retension Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Retension Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Retension Pharmaceuticals changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Retension Pharmaceuticals changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.